Determining Treatment Duration for Transplant-Ineligible Multiple Myeloma

Video

An expert describes how he determines treatment duration and discontinuation for transplant-ineligible multiple myeloma in his clinical practice.

Recent Videos
Isatuximab plus VRd triplet therapy did not significantly increase toxicity in patients with transplant-ineligible multiple myeloma in the IMROZ trial.
Isatuximab quadruplet therapy for patients with multiple myeloma prolonged progression-free survival when compared with VRd triplet therapy.
Samantha Shenoy, NP, MSN, suggests that support groups may help comfort patients experiencing adverse effects negatively impacting quality of life.
Samantha Shenoy, NP, MSN, emphasized educating patients with multiple myeloma to help prepare them for potential taste alterations after talquetamab.
Samantha Shenoy, NP, MSN, indicated that neurological issues were not prevalent with talquetamab, despite occurrences with other bispecifics antibodies.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
A panel of 5 experts on multiple myeloma
A panel of 5 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Related Content
Multiple myeloma

HDP-101 Demonstrates Preliminary Efficacy in R/R Multiple Myeloma

Russ Conroy
October 2nd 2024
Article

Investigators anticipate launching the dose-expansion portion of the phase 1 HDP-101-01 trial in 2025.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

James R. Berenson, MD, FACP
September 30th 2024
Podcast

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Determining Administration of BCMA, T-Cell Engagers in R/R Multiple Myeloma

Determining Administration of BCMA, T-Cell Engagers in R/R Multiple Myeloma

ONCOLOGY Staff
September 27th 2024
Article

Experts in multiple myeloma discussed optimal dosing strategies for bispecific antibodies for patients with relapsed/refractory multiple myeloma.

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice

Ishmael Applewhite, BSN, RN-BC, OCN;Leslie Bennett, MSN, RN;Kathy Mooney, MSN, RN, ACNS-BC, BMTCN®, OCN®
May 6th 2024
Podcast

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Combining talquetamab with teclistamab elicits responses even among those with extramedullary disease in the RedirecTT-1 trial.

Talquetamab Combo Yields Enduring Responses in R/R Multiple Myeloma

Russ Conroy
September 27th 2024
Article

Combining talquetamab with teclistamab elicits responses even among those with extramedullary disease in the RedirecTT-1 trial.

Multiple myeloma

Daratumumab Regimens Improve Depth, Durability of MRD-Negativity Rates in Newly Diagnosed Multiple Myeloma

Harrison Widelitz
September 26th 2024
Article

Extended follow-up from the CASSIOPEIA trial illustrates the PFS and MRD benefits of daratumumab-based induction/consolidation and maintenance therapy.